Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia.
BMC Res Notes
; 17(1): 60, 2024 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-38429779
ABSTRACT
OBJECTIVE:
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH inhibitor treatment was initiated in 32 patients with chronic HF complicated by renal anemia and were followed up for 3 months.RESULTS:
Hematocrit and hemoglobin levels markedly improved 3 months after HIF-PH inhibitor treatment. However, levels of NT-proBNP, which is an indicator of HF, did not decrease considerably. Based on the rate of change in NT-proBNP, we divided the patients into "responder" and "non-responder" groups. The results showed that considerably more patients had a ferritin level of less than 100 ng/mL in the non-responder group at baseline. There were substantially more patients with TSAT of less than 20% in the non-responder group at 1 month after HIF-PH inhibitor treatment. The cut-off values to maximize the predictive power of ferritin level at baseline and TSAT value at 1 month after treatment were 41.8 ng/ml and 20.75. HIF-PH inhibitor treatment can be expected to be effective for improving both anemia and HF if ferritin≥41.8 ng/ml at baseline or TSAT≥20.75 at 1 month after treatment.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Insuficiência Renal Crônica
/
Inibidores de Prolil-Hidrolase
/
Insuficiência Cardíaca
/
Anemia
Limite:
Humans
Idioma:
En
Revista:
BMC Res Notes
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão